Form 4: Oncology Institute Director Receives Stock Grant
Insider Transaction (Form 4)
Mark Stolper, a Director of Oncology Institute, Inc., received 31,124 shares of common stock on July 27, 2026.
Summary
- Grant/award: acquired 31,124 Common Stock on July 27, 2026; holds 56,957 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mark Stolper — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-27 | Grant/award | Common Stock | 31,124 | — | — | 56,957 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-27 | Grant/award (31,124 shares) |
Keywords
insider transaction, Form 4, TOI, Oncology Institute, Inc., neutral, Mark Stolper
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.